An observational study in Rectal Cancer, sponsored by Medical University of Vienna. Completed. Per ClinicalTrials.gov, last updated 2022-05-19.
Sponsored by Medical University of Vienna · Observational
The fistula-associated anal adenocarcinoma is rare in patients suffering from anal fistulas. There is only little data available for this patient collective making characterization and management of this disease difficult. Late diagnosis and advanced tumor stage at diagnosis result in poor clinical outcome. It is the purpose of this study to evaluate patients clinically diagnosed with a FAAC and to further perform a histopathological characterization of the available tumor specimen.
All patients receiving surgery for an anal fistula in the years 1999 to 2019 at a tertiary university referral hospital were included in the analysis. A retrospective review of patients' charts was performed. Patients suffering from FAAC were eligible for histopathological analysis including immunohistochemistry and molecular profiling.
2,004 studies on the registry are indexed under Adenocarcinoma; 375 are open to participants now.
This study's enrollment of 1,004 is above the median of 153 across 332 observational studies indexed under Adenocarcinoma.
Browse Adenocarcinoma studies →Medical University of Vienna is the lead sponsor of 1,076 studies on the registry; 176 are open to participants now.
Counted across the registry records on this site, refreshed daily.
all patients receiving surgery for an anal fistula at a tertiary university referral hospital. Of those, patients suffering from fistula-associated anal cancer were eligible for further clinical and histopathological analysis
Exclusion Criteria:
fistula-associated anal adenocarcinoma (FAAC)
include and analyze all patients suffering from FAAC
Time frame: 1999-2019
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in May 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Medical University of Vienna